These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9731351)

  • 1. In vitro and in vivo dapsone release from hydroxyapatite reservoirs.
    Lasserre A; Berty S; Bajpai PK
    Biomed Sci Instrum; 1997; 33():149-54. PubMed ID: 9731351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro delivery of dexamethasone using hydroxyapatite reservoirs.
    Billotte WG; Bajpai PK
    Biomed Sci Instrum; 1997; 34():13-7. PubMed ID: 9603005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hydroxyapatite system for the continuous release of coumadin an anticoagulant.
    Tarr ER; Lasserre A; Szmulowicz U; Bajpai PK
    Biomed Sci Instrum; 1997; 33():143-8. PubMed ID: 9731350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A ceramic system for delivering interleukin-2.
    Smith SW; Billotte WG; Krane D; Sage K; Bajpai PK
    Biomed Sci Instrum; 1997; 34():65-9. PubMed ID: 9603014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyapatite ceramics for continuous delivery of heparin.
    Abrams L; Bajpai PK
    Biomed Sci Instrum; 1994; 30():169-74. PubMed ID: 7948632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a ceramic device for the continuous local delivery of steroids.
    Zafirau W; Parker D; Billotte W; Bajpai PK
    Biomed Sci Instrum; 1996; 32():63-70. PubMed ID: 8672691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parameters of protein delivery using hydroxyapatite in simulated body fluid.
    Tscholl B; Billotte WG; Reed D; Smith S; Kreinbrink K; Bajpai PK
    Biomed Sci Instrum; 1997; 34():70-5. PubMed ID: 9603015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biocompatibility of steroid-HA delivery system using adult castrated rams as a model.
    Benghuzzi H; England B
    Biomed Sci Instrum; 2001; 37():275-80. PubMed ID: 11347402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man.
    Coleman MD; Scott AK; Breckenridge AM; Park BK
    Br J Clin Pharmacol; 1990 Nov; 30(5):761-7. PubMed ID: 2271376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel drug delivery system for osteomyelitis using porous hydroxyapatite blocks loaded by centrifugation.
    Itokazu M; Matsunaga T; Kumazawa S; Yang W
    J Appl Biomater; 1995; 6(3):167-9. PubMed ID: 7492806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
    Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
    Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
    Jing Z; Zhang R; Zhou D; Chen J
    Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapsone induced acute photosensitivity dermatitis; a case report and review of literature.
    De D; Dogra S; Kaur I
    Lepr Rev; 2007 Dec; 78(4):401-4. PubMed ID: 18309716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat.
    Coleman MD; Russell RM; Tingle MD; Park BK
    J Pharm Pharmacol; 1992 Feb; 44(2):114-8. PubMed ID: 1352810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
    Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL
    Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone.
    Molinelli E; Paolinelli M; Campanati A; Brisigotti V; Offidani A
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):367-379. PubMed ID: 30943794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodegradable polymer-mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model.
    Chen FA; Kuriakose MA; Zhou MX; DeLacure MD; Dunn RL
    Head Neck; 2003 Jul; 25(7):554-60. PubMed ID: 12808659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selectively crosslinked hyaluronic acid hydrogels for sustained release formulation of erythropoietin.
    Motokawa K; Hahn SK; Nakamura T; Miyamoto H; Shimoboji T
    J Biomed Mater Res A; 2006 Sep; 78(3):459-65. PubMed ID: 16721757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.